Advantages | Characteristics |
Immunogenicity | • Induction of T and B cell-specific antigen |
Safety | • Inability to revert to virulent forms • The efficacy does not depends on toxic treatments • No observed significant adverse effects in clinical trials so far |
Construction | • Modifications in the transgene construct and vaccine can be made in short time • Optimization of plasmids and transcript is possible |
Stability | • Increased thermal stability―Long life time |
Mobility | • Easy storage and transport―No need for constant refrigeration |
Time manufacturing | • Rapid production and formulation • Reproducible in large-scale production |